Introduction to Evogene February 2017 Ofer Haviv, President & CEO

Safe Harbor statement 2 This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Table of contents Introduction Our technologyApplications and product programsSummary of investment highlights 3

Introducing Evogene 4 We are… A leading biotechnology company for the improvement of crop productivity and performance, addressing the world’s increasing demand for food, feed and fuel

Farmer’s needs 5 Farmer’s main inputs Fertilizers Agro-technical Seeds Ag-Chemicals Ag-Biologicals Precision tools Farmer’s target – maximize profit Increase crop yield  Reduce loses from stresses Minimize input expenses

6 The opportunityA dire need for innovation Crops’ full yield potential - yet to be captured Insect control - resistance to available commercial traits Extra yield of up to 60% - significant potential yet to be capturedResistance to available commercial solutions Emerging as promising tool to drive productivity – mainly due to microbiome & data revolutionStability limits applicability of existing products Seeds - $37B1 Ag-Chemicals - $56B2 Ag-Biologicals - $3B3 1 Source: Phillips McDougall , 20162 Source: Phillips McDougall, 20153 Source: Research & Markets, 2016

Evogene 'at a glance’ 7 An innovative, predictive discovery technology - applied to identify:Genetic elements for improved seedsChemical compounds for innovative Ag-ChemicalsMicrobes for novel Ag-BiologicalsStrategic collaborations with world-leading agriculture companies - including BASF, Bayer, DuPont, Monsanto, SyngentaRevenue model - based on licensing agreements, which typically include three main revenue streams:R&D payments - short termMilestone payments - mid termRoyalties from product sales - longer termFinancial fundamentals -Cash position - $93 million (September 30th, 2016) Projected cash use for 2016 - ~$15 millionListed on TASE (2007) and NASDAQ (2013) Innovative discovery technology Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds 7

Our revenue & business models 8 R&D payments R&D funding by partner Milestone fees Additional payments received upon achieving predetermined objectives Royalties Percentage of product sales by partner Collaboration timeline Early collaboration model Collaboration prior to initiating product discovery and development activity Late collaboration models Collaboration following internal product discovery and early development Advanced development & registration Discovery Early development Commercialization RD M R Revenue model RD M M M R E L1,2 Business model E L1 L2

Value creation per product program 9 Collaboration timeline Advanced development & registration Discovery Early development Commercialization RD M M M R E L1 L2 Value (illustration) Over 10 majorproduct programs

Table of contents Introduction Our technologyApplications and product programsSummary of investment highlights 10

11 Technology platform Interconnected Data HubComputational integration of ‘Big Data’ - currently four interconnected databases Science Multidisciplinary scientific approachdriving our R&D Dedicated ‘Big Data’On-going accumulation - public resources and problem-tailored experiments Driving Ag Innovationvia predictive biology Analysis platformsProprietary algorithms and modules to prioritize the best product candidates Chemical discovery Gene optimization Toxin discovery Gene discovery Stack discovery Target discovery

12 Plant validation systemsProviding proof for our predictions

13 Technology platformImplementation pathways 13 Innovative discovery technology Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds Platform outputs: Basis for development of innovative products

Table of contents Introduction Our technologyApplications and product programsSummary of investment highlights 14

15 15 Innovative discovery technology Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds Platform outputs: Basis for development of innovative products Application pathways

Improved seeds - market and unmet needs 16 ~$37B* in 2015 Innovation potential Basic seed Seed traits $0.5B $3.2B Insect resistance $1.5B $3.5B Herbicide tolerance $1.2B $1.5B Yield $0.45B $0.65B Drought tolerance $1B $1B Disease resistance Corn Soy Examples – trait values Existing Products Potential yet tobe captured Broad commercial potential for bringing ‘breakthrough’ traits to the seed market * Source: Phillips McDougall , 2015 Biotech Seeds

17 Improved seeds - activities and achievements Product trait programs - focus on corn, soy, wheat, cotton and canola Yield and abiotic stress – since 2004Disease resistance - since 2007Insect resistance – since 2014Main achievements - Most advanced gene in Phase II of developmentCollaborations with industry leadersStrong IP portfolio - over 4000 genes under patent protectionOver 1000 genes under target crop validation by partners Overview Traits Yield Abiotic stress Insect resistance Diseases resistance Improvedseeds Example: Monsanto-Evogene collaboration Collaboration period - 8 yearsObjective - improved seeds via biotechnologyCrops - Corn, soybean, cotton, canolaTraits - Yield, drought tolerance, fertilizer utilizationInsect resistance – Fusarium resistance in cornKey terms - R&D and up-front payments - total c.$68MMilestone payments + royalties from sales$30M equity investment (including $12M in IPO) Gene discovery and trait optimization Development and commercialization Model plant validation Target plant validationand development Computational discovery Partners

18 Improved seeds - selected results Genes demonstrated potential to achieve yield enhancement in target crops Additional optimization & development towards phase 2 Pathforward Further optimization and validation in plants towards licensing agreement Yield Insect resistance (internal program) Abiotic stresses Internal program collaboration Novel toxins showed activity against Lepidoptera and Coleopteran insects Pathforward

19 Improved seeds - upcoming value drivers Improvedseeds Trait Gene advancement - Gene advancement within early development (phase 1)Gene advancement to advanced development (phase 2) Toxin advancement - optimization and licensing -Entry into strategic, product development collaborationToxin advancement within discovery – including optimization and testing in target cropsToxin advancement to early development (phase 1) Yield Disease Resistance Insect Resistance Gene advancement - Gene advancement within early development (phase 1)Gene advancement to advanced development (phase 2) Abiotic stress Discovery Early Development Advanced development & registration Commercialization

20 Application pathways 20 Innovative discovery technology Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds Platform outputs: Basis for development of innovative products

21 ~$37B* in 2015 Innovation potential Key challenge - finding the next generation of novel herbicide Herbicides Insecticides Fungicides Others Glyphosate - leading herbicide with >$5B sales, yet broadly increasing weed resistance Dire need for novel herbicides due to increasing resistance Source - International Survey of Herbicide Resistant Weeds, www.weedscience.org/graphs/soagraph.aspx (2013) * Source: Phillips McDougall , 2015 Innovative Ag-Chemicals - market and unmet needs

Innovative Ag-Chemicals - activities & achievements Product programs – Novel herbicides with new Mode of Action (MOA) - since 2013Main achievements – Strategic collaboration with BASF (signed in 2015)Discovery and validation in plants of several novel herbicide targets Tens of discovered small molecules showing potential as active ingredient in novel herbicide Overview inhibition Herbicide targetA macro-molecule within the weed essential for its life Herbicide chemicalInhibiting target leads to weed death Weeds Example: BASF-Evogene collaboration Collaboration period - 3 yearsObjective - herbicides with new MOA Activities - Evogene to identify novel targets and target-linked chemicals candidatesBASF to screen & validate the candidate chemicals and further develop successful candidates towards commercial products InnovativeHerbicide Chemical screens Target and chemical candidates discovery Screening, development and commercialization Computational target & chemical discovery Targets &chemicals Chemicalhits Development,regulation& registration 22

Targets successfully validated in plants Chemicals displayed herbicide activityagainst weeds Innovative Ag-Chemicals - selected results 23 Advancement of targets and chemical hits – optimization and additional plant testing Path forward *Prior to optimization * Results from Evogene’s internal activity

Innovative Ag-Chemicals - upcoming value drivers 24 InnovativeAg-Chemicals Product Discovery Early Development Advanced development & registration Commercialization Chemical hit advancement - Advanced hits - following optimization Initial leads - optimized hits with desired plant efficacy Collaborations -Expand existing or entry into additional collaborations Insecticides Consider entry into new segmentsDiscovery of novel insecticides/ fungicides Herbicides Fungicides

25 Application pathways 25 Innovative discovery technology Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds Platform outputs: Basis for development of innovative products

26 ~$3.2B* in 2015 Innovation potential Development of “next generation” Ag-Biological products * Source: Phillips McDougall , 2015 ~$9B ~$3.2B E Source – 2020 estimation based on integrated information of BCC Research, marketsandmarkets, Agropages and Phillips McDougall Relatively short time and low investment to marketNeed for novel solutions with stable performanceMicrobiome a promising source for innovation, now accessible via maturing technologies Novel Ag-Biologicals - market and potential Bio-stimulats Bio-pesticides

27 Novel Ag-Biologicals - activities and achievements Product programs - Bio-stimulant (mainly yield and abiotic stress) in corn, soy and wheat – since 2015Main achievements - 10’s of microbes showing consistent improvement of yield traits in greenhouse and fieldEstablishment infrastructure for product research and development - computational, tailored OMIC experiments, plant assays, formulation and fermentation 2OK isolated microbes from unique sourcing samples, with > 10K sequenced genomes Overview Crops Product Bio-stimulant X Internal Bio-stimulant discovery & development program Novel Biostimulant Internal Evogene program - including downstream activityLicense out to partner – late collaboration modelExpected time to product - ~5 years Discovery Early Development12 months Development stage 112-18 months Development stage 212-18 months Hit Team Lead Pre-commercializtion24 months Pre Product Product Current Status

28 Novel Ag-Biologicals - selected results 10’s of microbial Hits displaying positive results in corn field trials EVO-0685 No treatment Example: EVO-0685 – improved ear size and weight at harvest resulted with 17% increase of yield per plant Combination of microbial hits, additional testing along with product development activities (upscale, fermentation & formulation) Ears at harvest Path forward

Novel Ag-Biologicals - upcoming value drivers Product Discovery Early Development Advanced development & registration Commercialization Bio-stimulants Bio-pesticides Progress to advanced development - Advance Hits to Leads based on consortia (microbial team)Field testing & optimization development activity (fermentation & formulation) for Leads Consider entry into new segmentsDiscovery of novel microbial strains for bio-pesticides NovelAg-Biologicals 29

Table of contents Introduction Our technologyApplications and product programsSummary of investment highlights 30

Investment highlights 5 2 3 4 Strong balance sheet 1 Engine for next generation product development targeting multi-billion dollar ag markets Unique technology platform, combining expertise in plant science and cutting-edge computational tools Diversified product portfolio with multiple paths to milestone payments and royalties from commercialization Innovation partner of choice for industry leaders 31

Thank you. Contact:investors@evogene.comT: +972 8 931 1964